Prospective Prostate Cancer and Patient-reported Outcomes Registry
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Jan 4, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Prospective Prostate Cancer and Patient-reported Outcomes Registry, is exploring how a digital tool can help track the health and experiences of men diagnosed with localized or locally advanced prostate cancer. The goal is to gather important information about both medical outcomes and patients' personal experiences during their treatment. This study is currently recruiting male participants aged 65 to 74 who can read and understand Dutch, French, or English.
To be eligible for the trial, participants must have a confirmed diagnosis of localized or locally advanced prostate cancer and be able to provide informed consent, meaning they understand what the study involves and agree to take part. Unfortunately, individuals who have received prior treatment for prostate cancer or have certain mental health issues that might affect their ability to participate will not be eligible. If you join the study, you can expect to use the digital tool as part of your regular care, helping both you and your healthcare providers better understand your health journey.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Pathology confirmed diagnosis of localized or locally advanced prostate cancer
- • Being able to speak, read and understand Dutch, French, or English
- • Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he understands the purpose of, and is willing to participate in the study.
- Exclusion Criteria:
- • Patients with prior treatment for prostate malignancies will be excluded.
- • Dementia, mental alteration, or psychiatric pathology that can compromise informed consent from the patient and/ or adherence to the protocol and the monitoring of the trial
- • Patients who cannot submit themselves to following the protocol for psychological reasons, social, family, or geographical.
- • Persons deprived of liberty or under guardianship
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Vlaams Brabant, Belgium
Dendermonde, Oost Vlaanderen, Belgium
Brugge, West Vlaanderen, Belgium
Kortrijk, West Vlaanderen, Belgium
Patients applied
Trial Officials
Wouter Everaerts, MD, PhD
Principal Investigator
UZ Leuven / KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials